Pomalidomide
Other Immunosuppressants
Sold as POMALYST
- Drug class
- Other Immunosuppressants
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 97
- FDA reports (12 mo)
- 6,844
Overview
Plain-language summary, compiled from the cited regulatory records
Pomalidomide is a medication classified as an other immunosuppressant [1]. It is approved for treating adult patients with multiple myeloma (MM) who have previously undergone at least two therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression [1]. Pomalidomide is also indicated for patients with Kaposi sarcoma (KS) related to AIDS, following the failure of highly active antiretroviral therapy (HAART) [1].
This medication is available under various brand names [N]. In the past 12 months, there have been 6,844 adverse event reports associated with pomalidomide [2]. The most frequently reported adverse events include fatigue, death, off-label use, plasma cell myeloma, and pneumonia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 65 | May 22, 2026 |
| EU European Union | EMA | 6 | May 28, 2026 |
| US United States | FDA | 2 | January 30, 2026 |
| CA Canada | Health Canada | 24 | April 22, 2026 |
GBUnited Kingdom· MHRA
65 products
Uses
Pomalidomide Zentiva in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalidomide Zentiva in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
How to take
EUEuropean Union· EMA
6 products
Uses
Pomalidomide Teva in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Pomalidomide Teva in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
How to take
USUnited States· FDA
2 products
Uses
1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate.
2 ). 1 Multiple Myeloma Pomalidomide, in combination with dexamethasone, are indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
2 Kaposi Sarcoma Pomalidomide capsules are indicated for the treatment of: Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). Kaposi sarcoma (KS) in adult patients who are HIV-negative.
2 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
CACanada· Health Canada
24 products
24 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [4].
Brands in Canada (1)
Drug interactions
Known interactions involving Pomalidomide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB177801265 · revised January 23, 2026
- [2]European Medicines Agency · EMEA/H/C/006302 · revised May 28, 2026
- [3]FDA DailyMed · 0169dbda-53df-4c… · revised November 18, 2025 [PDF]
- [4]Health Canada (DPD) · 02419580 · revised August 21, 2025
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.